{"id":52959,"date":"2022-09-13T16:41:27","date_gmt":"2022-09-13T15:41:27","guid":{"rendered":"https:\/\/touchoncology.com\/?post_type=media_gallery&#038;p=52959"},"modified":"2022-09-13T16:44:36","modified_gmt":"2022-09-13T15:44:36","slug":"bernd-kasper-esmo-2022-defi-phase-3-trial-investigating-nirogacestat-versus-placebo-for-progressing-desmoid-tumors","status":"publish","type":"media_gallery","link":"https:\/\/touchoncology.com\/soft-tissue-tumours\/conference-hub\/bernd-kasper-esmo-2022-defi-phase-3-trial-investigating-nirogacestat-versus-placebo-for-progressing-desmoid-tumors\/","title":{"rendered":"Bernd Kasper, ESMO 2022: DeFi phase 3 trial investigating nirogacestat versus placebo for progressing desmoid tumors"},"content":{"rendered":"<p>Desmoid tumours are rare, locally aggressive soft-tissue tumours that are challenging to manage, due to lack of approved therapies, and variable presentation. <strong>Dr Bernd Kasper <\/strong>(Universit\u00e4tsmedizin Mannheim, Mannheim, Germany) joins touchONCOLOGY to discuss the phase 3 DeFi study, a global randomized, double-blind, placebo-controlled trial in adults with progressing desmoid tumours. The trial investigates nirogacestat, a novel oral gamma secretase inhibitor, that has shown antitumour activity in patients with desmoid tumours.<\/p>\n<p>The abstract entitled &#8216;<a href=\"https:\/\/s3.eu-central-1.amazonaws.com\/m-anage.com.storage.esmo\/static\/esmo2022_abstracts\/LBA2.html.pdf\" target=\"_blank\" rel=\"noopener\">DeFi: A phase III, randomized controlled trial of nirogacestat versus placebo for progressing desmoid tumors<\/a>&#8216; Abstract LBA2, was presented at <a href=\"https:\/\/www.esmo.org\/meetings\/esmo-congress-2022\" target=\"_blank\" rel=\"noopener\">European Society for Medical Oncology (ESMO) 2022<\/a>.<\/p>\n<p><strong>Questions<\/strong>:<\/p>\n<ol>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Could you tell us a little about desmoid tumours and the unmet needs in their treatment? (0:19)<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">What is nirogacestat and what is the rationale for its use in the treatment of desmoid tumours? (1:13)<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">What were the aims, design and eligibility criteria of the DeFi study? (1:52)<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">What were the efficacy and safety findings of the study? (2:40)<\/span><\/li>\n<\/ol>\n<p><strong>Disclosures<\/strong>: Bernd Kasper is a consultant for and receives grant\/research support from Springworks;\u00a0is on the advisory board for Bayer, Blueprint, Boehringer Ingelheim, Springworks, GSK, PharmaMar, and Ayala; invited Speaker for PharmaMar, Springworks, Ayala.<\/p>\n<p><strong>Support<\/strong>: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Katey Gabrysch.<\/p>\n<p><a href=\"https:\/\/touchoncology.com\/conference-hub\/?pagesLoaded=2&amp;post_type_filter=media_gallery,insight&amp;conference_filter=esmo-highlights\"><em><strong>Filmed in coverage of ESMO 2022<\/strong><\/em><\/a><\/p>\n<p><a href=\"https:\/\/touchoncology.com\/speciality\/soft-tissue-tumours\/\"><strong><em>Access more soft tissue tumours content here<\/em><\/strong><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Desmoid tumours are rare, locally aggressive soft-tissue tumours that are challenging to manage, due to lack of approved therapies, and variable presentation. Dr Bernd Kasper (Universit\u00e4tsmedizin Mannheim, Mannheim, Germany) joins touchONCOLOGY to discuss the phase 3 DeFi study, a global randomized, double-blind, placebo-controlled trial in adults with progressing desmoid tumours. The trial investigates nirogacestat, a [&hellip;]<\/p>\n","protected":false},"featured_media":52960,"template":"","class_list":["post-52959","media_gallery","type-media_gallery","status-publish","has-post-thumbnail","hentry","vocabulary_1-soft-tissue-tumours","video_categories-esmo-highlights"],"acf":[],"_links":{"self":[{"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media_gallery\/52959","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media_gallery"}],"about":[{"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/types\/media_gallery"}],"version-history":[{"count":5,"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media_gallery\/52959\/revisions"}],"predecessor-version":[{"id":52966,"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media_gallery\/52959\/revisions\/52966"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media\/52960"}],"wp:attachment":[{"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media?parent=52959"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}